Century Therapeutics, Inc. (IPSC)
Market Cap | 186.75M |
Revenue (ttm) | 1.37M |
Net Income (ttm) | -133.47M |
Shares Out | 84.50M |
EPS (ttm) | -2.21 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 142,578 |
Open | 2.390 |
Previous Close | 2.410 |
Day's Range | 2.210 - 2.400 |
52-Week Range | 1.280 - 5.510 |
Beta | 1.45 |
Analysts | Strong Buy |
Price Target | 14.17 (+541.18%) |
Earnings Date | Aug 7, 2024 |
About IPSC
Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relaps... [Read more]
Financial Performance
In 2023, IPSC's revenue was $2.24 million, a decrease of -57.01% compared to the previous year's $5.20 million. Losses were -$136.67 million, 4.38% more than in 2022.
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for IPSC stock is "Strong Buy." The 12-month stock price forecast is $14.17, which is an increase of 541.18% from the latest price.
News
![](https://cdn.snapi.dev/images/v1/0/b/press1-2458556.jpg)
Century Therapeutics Presents Interim Results from Phase 1 ELiPSE-1 Study at ASCO 2024 Annual Meeting
In ongoing dose escalation, CNTY-101 has demonstrated a manageable safety profile with no observed DLTs or GvHD and with majority of patients treated in outpatient setting
![](https://cdn.snapi.dev/images/v1/x/l/press17-2420586.jpg)
Century Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
- Announced plans to pursue additional autoimmune disease regulatory filings for its iPSC derived NK cell therapy, CNTY-101, beyond systemic lupus erythematosus (SLE)
![](https://cdn.snapi.dev/images/v1/q/9/conf20-2384912.jpg)
Century Therapeutics to Present at Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
PHILADELPHIA, April 23, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immu...
![](https://cdn.snapi.dev/images/v1/b/r/press14-2366789.jpg)
Century Therapeutics Strengthens Position in Autoimmune Disease with Strategic Pipeline Expansion Supported by $60 Million Private Placement and Acquisition of Clade Therapeutics
Century is pursuing additional autoimmune disease regulatory filings for its iPSC derived iNK cell therapy, CNTY-101, beyond CALiPSO-1 trial in SLE, based on the potential of its differentiated profil...
![](https://cdn.snapi.dev/images/v1/q/x/press2-2361844.jpg)
Century Therapeutics Presents New Preclinical Data Highlighting iPSC-derived Cell Therapy Platform Technology at the 2024 American Association for Cancer Research (AACR) Annual Meeting
PHILADELPHIA, April 08, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immu...
![](https://cdn.snapi.dev/images/v1/1/i/conf14-2330491.jpg)
Century Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
PHILADELPHIA, March 19, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immu...
![](https://cdn.snapi.dev/images/v1/3/7/press4-2323994.jpg)
Century Therapeutics Reports Full Year 2023 Financial Results and Provides Business Updates
- Presented initial data from Phase 1 ELiPSE-1 Trial of CNTY-101 in relapsed/refractory B-cell lymphomas demonstrating a favorable tolerability profile, early clinical activity and indication that All...
![](https://cdn.snapi.dev/images/v1/t/l/press17-2309850.jpg)
Century Therapeutics Announces Six Upcoming Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting
Posters will highlight Century's end-to-end cell therapy capabilities including expertise across iPSC reprogramming, gene editing, protein engineering, Allo-Evasion™ technology and computational biolo...
![](https://cdn.snapi.dev/images/v1/n/c/conf7-2254968.jpg)
Century Therapeutics to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
PHILADELPHIA, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immun...
![](https://cdn.snapi.dev/images/v1/h/l/press18-2190200.jpg)
Century Therapeutics Presents Initial Data from CNTY-101 Phase 1 ELiPSE-1 Trial Supporting the Potential for a Multi-Dosing Strategy for CAR iNK Enabled by Allo-Evasion™ Edits
– Data presented at 65 th ASH Annual Meeting show CNTY-101 was generally well tolerated at Dose Level 1 (100 million cells) in a high-risk, heavily pretreated R/R B-cell lymphoma patient –
![](https://cdn.snapi.dev/images/v1/0/f/press20-2185327.jpg)
Century Therapeutics Receives FDA Clearance of IND Application for CNTY-101 in Systemic Lupus Erythematosus
– Represents second IND clearance for CNTY-101, the Company's lead iPSC-derived CD19-targeted CAR NK cell product candidate, and first in an autoimmune and inflammatory disease indication –
![](https://cdn.snapi.dev/images/v1/9/e/conf6-2185340.jpg)
Century Therapeutics to Host Conference Call to Discuss Preliminary Clinical Data from Phase 1 ELiPSE-1 trial of CNTY-101 in Relapsed or Refractory B-cell Lymphomas and Planned Phase 1 Study in Systemic Lupus Erythematosus
PHILADELPHIA, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immun...
![](https://cdn.snapi.dev/images/v1/w/k/conf12-2166768.jpg)
Century Therapeutics to Present at the Piper Sandler 35th Annual Healthcare Conference
PHILADELPHIA, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immun...
![](https://cdn.snapi.dev/images/v1/s/f/press16-2149315.jpg)
Century Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates
- Brent Pfeiffenberger, Pharm.D., MBA, appointed Chief Executive Officer of Century Therapeutics - - Initial data from the ongoing Phase 1 ELiPSE-1 trial evaluating CNTY-101 in relapsed or refractory ...
![](https://cdn.snapi.dev/images/v1/a/h/press14-2149262.jpg)
Century Therapeutics and FUJIFILM Cellular Dynamics Announce Licenses for the Development and Commercialization of iPSC-Derived Cell Therapies in Autoimmune and Inflammatory Diseases
PHILADELPHIA and MADISON, Wis., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (NASDAQ: IPSC), an innovative clinical-stage biotechnology company developing induced pluripotent stem cell...
![](https://cdn.snapi.dev/images/v1/l/t/conf6-2077491.jpg)
Century Therapeutics to Present at the Chardan 7th Annual Genetic Medicines Conference
PHILADELPHIA, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative clinical-stage biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell th...
![](https://cdn.snapi.dev/images/v1/k/q/press19-2014403.jpg)
Century Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates
– Company remains on track to report initial data from Schedule A of the ongoing Phase 1 ELiPSE-1 trial of CNTY-101 in relapsed/refractory CD19 positive B-cell lymphomas by year end –
![](https://cdn.snapi.dev/images/v1/b/z/press7-1884729.jpg)
Century Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updates
– Preclinical data supporting selection of CNTY-101 as lead product candidate presented at AACR Annual Meeting –
![](https://cdn.snapi.dev/images/v1/w/k/conf13-1839080.jpg)
Century Therapeutics to Present at Chardan's 7th Annual Genetic Medicines & Cell Therapy Manufacturing Virtual Summit
PHILADELPHIA, April 17, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative clinical-stage biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell th...
![](https://cdn.snapi.dev/images/v1/d/j/press9-1833961.jpg)
Century Therapeutics Announces Leadership Changes
– Lalo Flores, Ph.D., steps down as Chief Executive Officer and member of Board of Directors; Greg Russotti, Ph.D., Chief Technology Officer, assumes role of ad-interim Chief Executive Officer –
![](https://cdn.snapi.dev/images/v1/b/u/press16-1799724.jpg)
Century Therapeutics Reports Full Year 2022 Financial Results and Provides Business Updates
- Phase 1 ELiPSE-1 trial of CNTY-101 in relapsed/refractory CD19 positive B-cell lymphomas underway -
![](https://cdn.snapi.dev/images/v1/r/q/conf7-1798854.jpg)
Century Therapeutics to Present at the AACR Annual Meeting 2023
PHILADELPHIA, March 15, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative clinical-stage biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell th...
![](https://cdn.snapi.dev/images/v1/d/o/conf15-1761966.jpg)
Century Therapeutics to Present at Upcoming Investor Conferences
PHILADELPHIA, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative clinical-stage biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell the...
![](https://cdn.snapi.dev/images/v1/n/q/press2-1743993.jpg)
Century Therapeutics Announces First Patient Dosed in First-In-Human Phase 1 ELiPSE-1 Trial Evaluating CNTY-101 in Relapsed or Refractory CD19 Positive B-cell Lymphomas
– CNTY-101 is the first cell therapy product candidate engineered with six precision gene edits including a CD19-CAR, Allo-Evasion™ technology, IL-15 cytokine support and a safety switch –
![](https://cdn.snapi.dev/images/v1/o/o/image19-1714581.jpg)
5 Health Care Stocks That Are Diving - And May Rally
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.